Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 22, 2026
Exact Sciences Announces Third Quarter 2020 Results
07:01am, Tuesday, 27'th Oct 2020
MADISON, Wis., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $408.4 million for the third quarter ended September 30, 2020, co
Was The Smart Money Right About Crowding Into EXACT Sciences Corporation (EXAS)?
09:01pm, Monday, 26'th Oct 2020
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2020 Update
10:49am, Friday, 11'th Sep 2020
Halvorsen's 13F portfolio value increased from $19.21B to $23.14B. The number of positions increased from 64 to 71.
How Moderna Will Fare After Posting Strong Clinical Results
03:37am, Friday, 28'th Aug 2020
Moderna posted strong clinical results that failed to lift shares. Phase 3 results will follow over the next two years.
Exact Sciences: Cologuard's Prospects In 2021-2022
02:08pm, Wednesday, 26'th Aug 2020
Cologuard is Exact Sciences Corporation’s highly sensitive and accurate, noninvasive, multi-target stool DNA test for screening and diagnosis of colorectal cancer in average-risk patients.
James Edward Doyle Sells 2,539 Shares of EXACT Sciences Co. (NASDAQ:EXAS) Stock
10:06pm, Sunday, 09'th Aug 2020
EXACT Sciences Co. (NASDAQ:EXAS) Director James Edward Doyle sold 2,539 shares of EXACT Sciences stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $94.00, for
EXACT Sciences Co. (NASDAQ:EXAS) Shares Bought by Nisa Investment Advisors LLC
06:30am, Wednesday, 05'th Aug 2020
Nisa Investment Advisors LLC increased its holdings in EXACT Sciences Co. (NASDAQ:EXAS) by 17.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 8,558 shares o
EXACT Sciences (NASDAQ:EXAS) PT Raised to $120.00
06:18am, Tuesday, 04'th Aug 2020
EXACT Sciences (NASDAQ:EXAS) had its price objective increased by Citigroup from $110.00 to $120.00 in a research report sent to investors on Friday, The Fly reports. Citigroup currently has a buy rat
Exact Sciences: A Hidden Gem In The Biotech Space (NASDAQ:EXAS)
07:43pm, Monday, 03'rd Aug 2020
Exact Sciences operates in the biotechnology industry offering cancer screening and diagnostic test products.
Exact Sciences A Better Near-Term Capital Gain Buy Than DexCom Inc. (NASDAQ:EXAS)
06:22pm, Monday, 03'rd Aug 2020
Medical Diagnostic & Research companies tend not to be involved in the Covid-19 virus vaccine race, but have their own life-saving results competitions.
Exact Sciences (EXAS) Q2 2020 Earnings Call Transcript
08:03am, Saturday, 01'st Aug 2020
EXAS earnings call for the period ending June 30, 2020.
Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines
04:13pm, Friday, 31'st Jul 2020
Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.
Thermo Fisher Long Case: Trajectory Is Clear, Buy On Value
03:50pm, Friday, 31'st Jul 2020
Strong quarter exit and clear guidance for Q4 2020 on the back of $1.3 billion in COVID-19 related sales YTD.
Why Exact Sciences pivoted into COVID-19 testing
03:13pm, Friday, 31'st Jul 2020
Health screening company Exact Sciences CEO Kevin Conroy speaks with Yahoo Finance’s Alexis Christoforous, Brian Sozzi and Anjalee Khemlani
